Call us 24/7

Clinical trials

Filters

35 Clinical Trials

This study in patients with relapsed/refractory follicular lymphoma who have undergone at least three lines of therapy. Patients will receive abexinostat 80 mg (4 × 20 mg tablets) twice a day (BID) in a "one week on, one week off" schedule.

The study will compare the efficacy and safety of pembrolizumab plus trastuzumab in combination with standard of care (SOC) chemotherapy versus trastuzumab in combination with SOC chemotherapy in participants with HER2-positive gastric cancer. The primary hypotheses of the study are that pembrolizumab plus trastuzumab in combination with chemotherapy is superior to trastuzumab plus chemotherapy in terms of 1) progression free survival (PFS) per Response Evaluation Criteria in Solid Tumors 1.1 (RECIST 1.1) as assessed by blinded independent central review (BICR), and 2) overall survival (OS).

This is an open-label, nonrandomized, phase 1 dose escalation, dose expansion, and phase 2 study targeting tumors with FGF/FGFR aberrations. The purpose of the study is to evaluate the safety, tolerability, PK, pharmacodynamic, and anti-tumor activity of TAS-120 in patients with advanced solid tumors with and without FGF/FGFR-related abnormalities.

Accepting new patients

This multicenter, non-randomized, open-label study will evaluate the efficacy and safety of six treatment regimens in participants with advanced solid tumors for whom therapies that will convey clinical benefit are not available and/or are not suitable options per the treating physician's judgment.

This Phase 1/2 study will evaluate the safety, efficacy, PK, and PD of FT-2102 as a single agent or in combination with azacitidine or cytarabine.

The purpose of this study is to determine whether the combination of pevonedistat and azacitidine improves overall response rate and whether the combination of pevonedistat and azacitidine improves event-free survival when compared with single-agent azacitidine.

Accepting new patients

The study will be conducted in two parts:

The purpose of part 1 is to assess the safety and tolerability of irinotecan liposome injection monotherapy and to determine the irinotecan liposome injection monotherapy dose for part 2 of the study.

The purpose of part 2 is to assess irinotecan liposome injection versus intravenous topotecan in patients with small cell lung cancer who have progressed on or after platinum-based first-line therapy.

Accepting new patients

This trial will evaluate the safety and efficacy of pembrolizumab (MK-3475) in combination with platinum doublet neoadjuvant chemotherapy before surgery (neoadjuvant phase), followed by pembrolizumab alone after surgery (adjuvant phase) in participants with resectable stage IIB or IIIA non-small cell lung cancer (NSCLC).

Accepting new patients

This is a phase III, randomized, double-blind, placebo-controlled, multinational, and multicenter study to evaluate the efficacy of rovalpituzumab tesirine as maintenance therapy following first-line platinum-based chemotherapy.

Coming soon

This is a trial in adult participants with unresectable, locally advanced, stage III non-small cell lung cancer (NSCLC) treated with pembrolizumab in combination with platinum doublet chemotherapy and standard thoracic radiotherapy followed by pembrolizumab monotherapy. The primary hypothesis of the trial is that within each platinum doublet chemotherapy cohort, the percentage of participants who develop grade 3 or higher pneumonitis is ≤10 percent.